Platelets, inflammation and tissue regeneration

Thrombosis and Haemostasis

Volumn 105, Issue SUPPL. 1, 2011, Pages 13-33

  Nurden, Alan T ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

Acquired diseases with platelet involvement; Angiogenesis; Immunity; Inflammation; Platelets; Wound healing

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADENOSINE DIPHOSPHATE; BETA TUBULIN; CD40 LIGAND; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; FIBRINOGEN RECEPTOR; GELATINASE A; GELATINASE B; GROWTH FACTOR; INTERSTITIAL COLLAGENASE; MEMBRANE RECEPTOR; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR AB; RANTES; SEROTONIN; SNARE PROTEIN; STROMELYSIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; THROMBOXANE A2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNINDEXED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; AUTACOID;

ALLERGY; ALZHEIMER DISEASE; ANGIOGENESIS; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLEEDING; COMPLEMENT SYSTEM; CROHN DISEASE; FIBRINOLYSIS; GRAFT REJECTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER DISEASE; LUNG DISEASE; LYSOSOME; MICROORGANISM; MULTIPLE SCLEROSIS; NEOPLASM; OSSIFICATION; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SKIN DISEASE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; TISSUE REGENERATION; WOUND HEALING; ANIMAL; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEOPLASMS; PLATELET ACTIVATION; REGENERATION;

EID: 79961016308     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/THS10-11-0720     Document Type: Article

References (253)

1. Weyrich A, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897-1905.
2. Nurden AT, Nurden P, Sanchez M, et al. Platelets and wound healing. Front Biosci 2008; 13: 3525-3548.
3. Zhang Q, Peyruchaud O, French KJ, et al. Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a Rho-dependent signal pathway. Blood 1999; 93: 2984-2990.
4. Takeya H, Gabazza EC, Aoki S, et al. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood 2003; 102: 1693-1700.
5. Ryo J, Kim HJ, Chang E-J, et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J 2006; 25: 5840-5851.
6. Panetti TS, Hannah DF, Avraamides C, et al. Extracellular matrix molecules regulate endothelial cell migration stimulated by lysophosphatidic acid. J Thromb Haemost 2004; 2: 1645-1656.
7. Boucharaba A, Serre C-M, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-1725.
8. Kulkarni S, Woollard KJ, Thomas S, et al. Conversion of platelets from a pro-aggregatory to a pro-inflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. Blood 2007; 110: 1879-1886.
9. Lefebvre JS, Marleau S, Milot V, et al. Toll-like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B4 and platelet-activating factor. FASEB J 2010: 24: 637-647.
10. Baldassarri S, Bertoni A, Bagarotti A, et al. The endocannabinoid 2-arachidonyl glycerol activates human platelets through non-CB1/CB2 receptors. J Thromb Haemost 2008; 6: 1772-1779.
11. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-2104.
12. Reed GL. Platelet secretory mechanisms. Semin Thromb Hemost 2004; 30: 441-450.
13. Kahner BN, Shankar H, Murugapppan S, et al. Nucleotide receptor signalling in platelets. J Thromb Haemost 2006; 4: 2317-2326.
14. Grenegard M, Vretenbrant-Oberg K, Nylander M, et al. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine. J Biol Chem 2008; 283: 18493-18504.
15. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002; 22: 364-373.
16. Lansdown AB. Calcium: a potential central regulator in wound healing in the skin. Wound Repair Regen 2002; 10: 271-285.
17. Caen J, Wu Q. Hageman factor, platelets and polyphosphates, early history and recent connection. J Thromb Haemost 2010; 8: 1670-1674.
18. Murata S, Ohkohchi N, Matsuo R, et al. Platelets promote liver regeneration in early period after hepatectomy in mice. World J Surg 2007; 31: 808-816.
19. Lang PA, Contaldo C, Georgiev P, et al. Aggravation of viral hepatitis by plateletderived serotonin. Nat Med 2008; 14: 756-761.
20. Blair P, Flaumenhaft R. Platelet α-granules: Basic biology and clinical correlates. Blood Rev 2009; 23: 177-189.
21. Richardson JL, Shivdasani RA, Boers C, et al. Mechanisms of organelle transport and capture along proplatelets during platelet production. Blood 2005; 106: 4066-4075.
22. Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15: 665-673.
23. Hourdillé P, Hasitz M, Belloc F, et al. Immunocytochemical study of the binding of fibrinogen and thrombospondin to ADP-and thrombin-stimulated human platelets. Blood 1985; 65: 912-920.
24. Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 2007; 5: 2009-2016.
25. Italiano Jr JE, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
26. Ma L, Perini R, McKnight W, et al. Proteinase-activated receptors 1 and 4 counterregulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 2005; 102: 216-220.
27. Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 2008; 28: 1920-1927.
28. Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb Res 2010; 125: 292-296.
29. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointimal formation after arterial injury. Circulation 2002; 106: 1523-1529.
30. Breland UM, Michelson AE, Skjelland M, et al. Raised MCP-4 levels in asymptomatic carotid atherosclerosis: an inflammatory link between platelet and monocyte activation. Cardiovasc Res 2010; 86: 265-273.
31. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-RNA splicing in anucleate platelets. Cell 2005; 122: 379-391.
32. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
33. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111: 5271-5281.
34. von Hundelshausen P, Koenen RR, Weber C. Platelet-mediated enhancement of leukocyte adhesion. Microcirculation 2009; 16: 84-96.
35. Langer HF, Daub K, Braun G, et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol 2007; 27:1463-1470.
36. Sudhof TC, Rothman JE. Membrane fusion: grappling with SNARE and SM proteins. Science 2009; 323: 474-477.
37. Ren Q, Barber HK, Crawford GL, et al. Endobrevin/VAMP-8 is the primary v-SNARE for the platelet release reaction. Mol Biol Cell 2007; 18: 24-33.
38. Lemmons PP, Chen D, Whiteheart SW. Molecular mechanisms of platelet exocytosis: requirements for α-granule release. Biochem Biophys Res Commun 2000; 267: 875-880.
39. Tolmachova T, Abrink M, Futter CE, et al. Rab27b regulates number and secretion of dense granules. Proc Natl Acad Sci USA 2007; 104: 5872-5877.
40. Schoenwaelder SM, Yuan Y, Josefsson EF, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-666.
41. Dean WL, Lee MJ, Cummins TD, et al. Proteomic and functional characterization of platelet microparticle size classes. Thromb Haemost 2009; 102: 711-718.
42. Doeuvre L Plawinski L, Toti F, et al. Cell-derived microparticles: a new challenge in neuroscience. J Neurochem 2009; 110: 457-468.
43. Janowska-Wieczorek A, Marquez-Curtis L, Wieczorek M, et al. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2005; 46: 1199-1209.
44. Dashevsky O, Varon D, Brill A. Platelet-derived microparticles promote invasiveness of prostrate cancer cells with upregulation of MMP-2 production. Int J Cancer 2009; 14: 1773-1777.
45. Horstman LL, Jy W, Ahn YS, et al. Role of platelets in neuroinflammation: a wideangle perspective. J Neuroinflammation 2010; 7: 10.
46. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-RNA splicing in anucleate platelets. Cell 2005; 122: 379-391.
47. Schwertz H, Tolley ND, Foulks JM, et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006; 203: 2433-2440.
48. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010; 67: 525-544.
49. Beaulieu LM, Freedman JE. The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. Thromb Res 2010; 125: 205-209.
50. Aslam R, Speck ER, Kim M, et al. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107: 637-641.
51. Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost 2008; 6: 415-420.
52. Clark SR, Ma AC, Taverner SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med 2007; 13: 463-469.
53. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
54. Preston RJ, Tran S, Johnson JA, et al. Platelet factor 4 impairs the anticoagulant activity of activated protein C. J Biol Chem 2009; 284: 5869-5875.
55. Blair P, Rex S, Vitseva O, et al. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res 2009; 104: 346-354.
56. Kälvegren H, Skoglund C, Helldahl C, et al. Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca2+ mobilization, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation. Thromb Haemost 2010; 103: 398-407.
57. Jimenez-Dalmaroni MJ, Xiao N, Corper AL, et al. Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS One 2009; 4: e7411.
58. Washington AV, Schubert RL, Quigley L, et al. A TREM family member, TLT-1 is found exclusively in the α-granules of megakaryocytes and platelets. Blood 2004; 104: 1042-1047.
59. Washington AV, Gibot S, Acevedo I, et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest 2009; 119: 1489-1501.
60. Haselmayer P, Grosse-Hovest L, von Landenberg P, et al. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 2007; 110: 1029-1035.
61. Flaujac C, Boukour S, Cramer-Bordé E. Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci 2010; 67: 545-556.
62. Chaipan C, Soilleux EJ, Simpson P, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type I capture by platelets. J Virol 2006; 80: 8951-8960.
63. Gavrilovskaya IN, Gorbunova EE, Mackow ER. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. J Virol 2010; 84: 4832-4839.
64. Bridges DJ, Bunn J, van Mourik JA, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood 2010; 115:1472-1474.
65. McMorran BJ, Marshall VM, de Graafe C, et al. Platelets kill intra-erthyrocytic malarial parasites and mediate survival to infection. Science 2009; 323: 797-800.
66. Krijgsveld J, Zaat SA, Meeldijk J, et al. Thrombocidins, microbicidal proteins from human blood platelets are C-terminal deletion products of CXC chemokines. J Biol Chem 2000; 275: 20374-20381.
67. Iannacone M, Sitia G, Isogawa M, et al. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 2008; 105: 629-634.
68. Redland EK, Ueland T, Pedersen TM, et al. Activation of platelets by Aspergillus fumigatus and potential role of platelets in the immunopathogenesis of Aspergillosis. Infect Immun 2010; 78: 1269-1275.
69. Peerschke E, Yin AW, Ghebrehlwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47: 2170-2175.
70. Del Conde I, Cruz MA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201:871-879.
71. Licht C, Pluthero FG, Li L, et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009; 114: 4538-4545.
72. Hara T, Shimizu K, Ogawa F, et al. Platelets control leukocyte recruitment in a murine model of cutaneous arthus reaction. Am J Pathol 2010; 176: 259-269.
73. Niemann S, Kehrel BE, Heilmann C, et al. Pneumococcal association to platelets is mediated by soluble fibrin and supported by thrombospondin-1. Thromb Haemost 2009; 102: 735-742.
74. De Haas CJ, Weeterings C, Vughs MM, et al. Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibαand αIIbβ3. J Thromb Haemost 2009; 7: 1867-1874.
75. Miajlovic H, Zapotoczna M, Geoghegan JA, et al. Direct interaction of iron-regulated surface determinant IsdB of Staphylococcus aureas with the GPIIb-IIIa reecptor on platelets. Microbiology 2010; 156: 920-928.
76. Sprague DL, Sowa JM, Elzey BD, et al. The role of platelet CD154 in the modulation of adaptive immunity. Immunol Res 2007; 39: 185-193.
77. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105: 215-218.
78. Elzey BD, Schmidt NW, Crist MA, et al. Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood 2008; 111: 3684-3691.
79. Sprague DL, Elzey BD, Crist SA, et al. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 2008; 110: 5028-5036.
80. Urquizu-Pasilla M, Balada E, Cortès F, et al. Serum levels of soluble CD40 ligand at flare and at remission in patients with systemic lupus erythrematosus. J Rheumatol 2009; 36: 953-960.
81. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2008; 61: 122-131.
82. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
83. Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008; 111: 4958-4964.
84. Campbell RA, Overmyer KA, Selzman CH, et al. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009; 114: 4886-4896.
85. Zhao BQ, Chauhan AK, Canault M, et al. Von Willebrand factor-cleaving protease ADAMST13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-3334.
86. Beutler B. Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002; 9: 2-10.
87. Hu J, Van den Steen PE, Sang Q-XA, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature 2007; 6: 480-498.
88. Niessen F, Schaffner F, Furlan-Fregula C, et al. Dendritic cell PAR1-SIP3 signalling couples coagulation and inflammation. Nature 2008; 452: 654-658.
89. Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009; 105: 128-137.
90. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-1262.
91. May AE, Seizer P, Gawaz M. Platelets: Inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: 5-10.
92. Podrez EA, Byzova TV, Febbralo M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007; 13: 1086-1095.
93. Ma Y, Ashraf MZ, Podrez EA. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. Blood 2010; 116: 1932-1941.
94. Gunarsson P, Levander L, Pählsson P, et al. Alpha(1)-acid glycoprotein (AGP)-induced platelet shape change involves the Rho/Rho kinase signalling pathway. Thromb Haemost 2009; 102: 694-703.
95. O'Connor R, Cryan LM, Wynne K, et al. Proteomics strategy for identifying candidate bioactive proteins in complex mixtures: Application to the platelet releasate. J Biomed Biotechnol 2010; 2010: 107859.
96. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004; 92: 459-466.
97. McEver RP. Rolling back to neutrophil adhesion. Nat Immunol 2010; 11: 282-284.
98. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000; 101: 2290-2295.
99. Ridker P, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495.
100. Kisucka J, Chauhan AK, Zhao AK, et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009; 113: 6015-6022.
101. André P, Hartwell D, Hrachoinova I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000; 97: 13835-13840.
102. Woollard KJ, King D, Kulkarni S, et al. Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ Res 2006; 98:149-158.
103. Davi G, Romano M, Mazzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-957.
104. Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol 2009; 30: 165-172.
105. Viallard JF, Solanilla A, Gauthier N, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99: 2612-2614.
106. Crist SA, Sprague DL, Ratliff TL. Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood 2008; 111: 3553-3561.
107. Choi WS, Jeon OH, Kim DS. CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin αIIbβ3. J Thromb Haemost 2010; 8: 1364-1371.
108. Antoniades C, Bakogiannis C, Tousoulis D, et al. The CD40/CD40L system: Linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-677.
109. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
110. Pluvinet R, Oliver R, Krupinski J, et al. CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood 2008; 112: 3624-3637.
111. André P, Prasad KC, Denis CV, et al. CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism Nat Med 2002; 8: 247-252.
112. Prasad KS, André P, He M, et al. Soluble CD40L induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003; 100: 12367-12371.
113. May AE, Kalsch T, Massberg S, et al. Engagement of glycoprotein IIb/IIIa (αIIbβ3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002; 106: 2111-2117.
114. Chen C, Chai H, Wang X, et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008; 112: 3205-3216.
115. Chai H, Aghaie K, Zhou W. Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration. Surgery 2009; 146: 5-11.
116. Donners MM, Beckers L, Lievens D, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 2008; 111: 4596-4604.
117. Li G, Sanders JM, Bevard MH, et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 2008; 172: 1141-1152.
118. Zirlak A, Maier C, Gerdes N, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007; 115: 1571-1580.
119. Léveillé C, Bouillon M, Guo W, et al. CD40 ligand binds to α5β1 and triggers cell signaling. J Biol Chem 2007; 282: 5143-5151.
120. Ferro D, Loffredo L, Polimeni L, et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 2007; 27: 2763-2768.
121. Kageyama K, Nakajima Y, Shibasaki M, et al. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total hip arthroplasty. J Thromb Haemost 2007; 5: 738-745.
122. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 108: 2455-2462.
123. Chauhan AK, Kisucka J, Brill A, et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205: 2065-2074.
124. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. New Engl J Med 2006; 354: 1927-1935.
125. Bernard JJ, Seweryniak KE, Koniski AD, et al. Foxp3 regulates megakaryopoiesis and platelet function. Arteriscler Thromb Vasc Biol 2009; 29: 1874-1882.
126. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. J Med Genet 2002; 39: 537-545.
127. Lambert MP, Rauova L, Bailey M, et al. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood 2007; 110: 1153-1160.
128. Natal C, Restituto P, Inigo C, et al. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrionol Metab 2008; 93: 2319-2327.
129. Unek IT, Bayraktar F, Solmaz D, et al. Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism 2010; 59: 305-313.
130. Lopez-Vilchez I, Escolar G, Diaz-Ricart M, et al. Tisssue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thromb Haemost 2007; 97: 202-211.
131. Dale GL. Coated platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 2185-2192.
132. Busso N, Chobaz-Péclat V, Hamilton J, et al. Essential role of platelet activation via protease activated receptor 4 in tissue factor-mediated inflammation. Arthritis Res Ther 2008; 10: R42.
133. Lay AJ, Donahue D, Tsai MJ, et al. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007; 109: 1984-1991.
134. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40L in the induction of monocyte tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328.
135. Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
136. Taylor FBJ, Chang A, Ruf W, et al. Lethal E coli septic shock shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
137. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53: 313-325.
138. Maroney SA, Haberichter SL, Friese P, et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007; 109: 1931-1937.
139. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-629.
140. Levesque J-P, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104: 65-72.
141. Hu J, Van den Steen PE, Sang Q-XA, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature 2007; 6: 480-498.
142. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and-2. Throm Haemost 1999; 82: 1730-1735.
143. Kazes I, Elalamy I, Sraer J-D, et al. Platelet release of trimolecular complex components MTI-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000; 96: 3064-3069.
144. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cell mediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24: 54-60.
145. Sawicki G, Sanders EJ, Salas E, et al. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 1998; 80: 836-839.
146. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009; 137: 332-343.
147. Bergmeier W, Piffath CL, Cheng G, et al. Tumour necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 2004; 95: 677-683.
148. Bender M, Hoffmann S, Stegner D, et al. Differentially regulated GPVI ectodomain shedding by multiple platelet-expresed proteins. Blood 2010; 116: 3347-3355.
149. Brill A, Chauhan AK, Canault M, et al. Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovasc Res 2009; 84: 137-144.
150. Neth P, Ciccarella M, Egea V, et al. Wnt signalling regulates the invasion capacity of human mesenchymal stem cells. Stem Cells 2006; 24: 1892-1903.
151. Steele BM, Harper MT, Macaulay IC, et al. Canonical Wnt signalling negatively regulates platelet function. Proc Natl Acad Sci USA 2009; 106: 19836-19841.
152. Murate T, Yamashita K, Isogai C, et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet-and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol 1997; 99: 181-189.
153. Radomski A, Jurasz P, Sanders EJ, et al. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol 2002; 137: 1330-1338.
154. Chirco R, Liu XW, Jung KK, et al. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25: 99-113.
155. Villeneuve J, Block A, Le Bousse M-C, et al. Tissue inhibitors of matrix metalloproteases in platelets and megakaryocytes: A novel organization for these secreted proteins. Exp Hematol 2009; 37: 849-856.
156. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007; 12: 2957-2966.
157. Lijnen HR. Pleiotropic functions of plasminogen inhibitor-1. J Thromb Haemost 2005; 3: 35-44.
158. Boulaftali Y, Adam F, Venise L, et al. Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood 2010; 115: 97-106.
159. Smith HW, Marshall CJ. Regulation of cell signaling by uPAR. Nat Rev Mol Cell Biol. 2010; 11: 23-38.
160. Garg N, Goyal N, Strawn TL, et al. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost 2010; 8: 1847-1854.
161. Eitzman DT, Westrick RJ, Xu Z, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 96: 4212-4215.
162. Dejouvencel T, Doeuvre L, Lacroix R, et al. Fibrinolytic cross-talk: a new mechanism for plasmin. Blood 2010; 115: 2048-2056.
163. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
164. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
165. Deregibus MC, Buttiglieri S, Russo S, et al. CD-40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem 2003; 278: 1808-1814.
166. Fang L, Yan Y, Komuves LG, et al. PDGF C is a selective alpha-platelet-derived receptor agonist that is highly expressed in platelet α-granules and vascular smooth muscle. Arterioscler Thromb Vasc Biol 2004; 24: 787-792.
167. Li L, Asteriou T, Bernert B, et al. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: importance of hyaluronan for the mitogenic response of PDGF-BB. Biochem J 2007; 404: 327-336.
168. Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004; 63: 226-235.
169. Walshe TE, Dole VS, Maharaj AS, et al. Inhibition of VEGF or TGF-βsignaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol 2009; 29: 1185-1192.
170. Min J-K, Lee LH, Kim Y-M, et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor kappaB pathway. Circ Res 2005; 96: 300-307.
171. Brunner G, Blakytny R. Extracellular regulation of TGF-beta activity in wound repair: growth factor latency as a sensor mechanism to injury. Thromb Haemost 2004; 92: 253-261.
172. Ahamed J, Janczak CA, Wittkowski KM, et al. In vitro and In vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring-and shear-dependent activation of platelet-derived TGF-β1. PLoS One 2009; 4: e6608.
173. Tran DQ, Andersson J, Wang R, et al. GARP (LRRC32) is essential for the surface expression of latent TGF-βon platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009; 106: 294-299.
174. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-48.
175. Isenberg JS, Calzada MJ, Zhou L, et al. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol 2005; 24: 110-123.
176. Bikfalvi A. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor 4 and the VEGF-VEGFR system. Biochem Pharmacol 2004; 68: 1017-1021.
177. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanism of action. Exp Cell Res 2006; 312: 594-607.
178. Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 2010; 21: 85-93.
179. Cicha I, Garlichs CD, Daniel WG, et al. Activated human platelets release connective tissue growth factor. Thromb Haemostasis 2004; 91: 755-760.
180. Thulin A, Ringvall A, Dimberg A, et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res 2009; 7: 1792-1802.
181. Kitaura H, Zhou P, Ross FP, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282-290
182. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factory in multiple myeloma. Blood 2000; 96: 671-675.
183. Klinger MH, Wilhelm D, Bubel S, et al. Immunocytochemical localization of the chemokines RANTES and MIP-1αwithin human platelets and their release during storage. Int Arch Allergy Immunol 1995; 107: 541-546.
184. Sipe JB, Zhang J, Waits C, et al. Localization of bone morphogenetic proteins (BMPs)-2,-4, and-6 within megakaryocytes and platelets. Bone 2004; 35: 1316-1322.
185. Taylor VL, Spencer EM. Characterization of insulin-like growth factor-binding protein-3 to a novel receptor on human platelet membranes. J Endocrinol 2001; 168: 307-313.
186. Fujiwara H. Do circulating blood cells contribute to maternal tissue remodeling and embryo-maternal cross-talk around the implantation period? Mol Hum Reprod 2009; 15: 335-343.
187. Echtler K, Stark K, Lorenz M, et al. Platelets contribute to postnatal occlusion of the ductus arteriosus. Nature Med 2010; 16: 75-82.
188. Carramolino L, Fuentes J, Garcia-Andrés C, et al. Platelets play an essential role in separating the blood and lymphatic vasculatures during embryonic angiogenesis. Circ Res 2010; 106: 1197-1201.
189. Uhrin P, Zaujec J, Breuss JM, et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood 2010; 115: 3997-4005.
190. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010; 116: 661-670.
191. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nature Rev Immunol 2006; 6: 508-519.
192. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury in mice. Circ Res 2002; 91: 845-851.
193. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004; 109: 1408-1414.
194. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med 1999; 5: 1135-1142.
195. Dole VS, Matuska J, Vasile E, et al. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 1111-1116.
196. Shattil SJ, Anaya-Galindo R, Bennett J, et al. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 636-643.
197. Smyth SS, Reis ED, Zhang W, et al. β3-integrin-deficient mice but not P-selectindeficient mice develop intimal hyperplasia after vascular injury. Correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation, 2001; 103: 2501-2507.
198. Evalangista V, Pamuklar Z, Piccoli A, et al. Src family kinases mediate neutrophil adhesion to adherent platelets. Blood 2007; 109: 2461-2469.
199. Massberg S, Schürzinger K, Lorenz M, et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 2005; 112: 1180-1188.
200. Huo Y, Schober A, Forlow SB, et al Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-67.
201. Oki T, Eto K, Izawa K, et al. Evidence that integrin αIIbβ3-dependent interaction of mast cells with fibrinogen exacerbates chronic inflammation. J Biol Chem 2009; 284: 3143-3172.
202. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischaemic stroke: novel insights and targets for treatment. Blood 2008; 112: 3555-3562.
203. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nature Reviews DrugDiscovery 2003; 2: 775-789.
204. Opdenakker G, Nelissen I, van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003; 2: 747-756.
205. Yong VW, Zabad RK, Agrawal S, et al. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulation. J Neurol Sci 2007; 259: 79-84.
206. Querfurth HW, LaFerla FM. Alzheimer's disease. New Engl J Med 2010; 362: 329-344.
207. Skovronsky DM, Lee M-Y, Pratico D. Amyloid precursor protein and amyloid β peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 2001; 276: 17036-17043.
208. Evin G, Holsiinger RM, Masters CL, et al. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res 2003; 74: 386-392.
209. Paul J, Strickland S, Melchior JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimers disease. J Exp Med 2007; 204: 1999-2008.
210. Klotz L, Diehl L, Dani J, et al. Brain endothelial PPAR gamma controls inflammation induced CD4+ T cell adhesion and transmigration in vitro. J Neuroimmunol 2007; 190: 34-43.
211. Currie J, Ramsbottom R, Ludlow H, et al. Cardio-respiratory fitness, habitual physical activity and serum brain derived neutrotrophic factor (BDNF) in men and women. Neurosci Letts 2009; 451: 152-155.
212. Fujimura H, Altar CA, Chen R, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87: 728-734.
213. Wiesner T, Bugl S, Mayer F, et al. Differential changes in platelet VEGF, TSP, CXCL12 and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis 2010; 27: 141-149.
214. Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115: 3427-3436.
215. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009; 22: 49-60.
216. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumour activity. Cancer Res 2009; 69: 7775-7783.
217. Kim YJ, Borsig L, Varki NM, et al. P-selectin deficiency attenuates tumour growth and metastasis. Proc Natl Acad Sci USA 1998; 95: 9325-9330.
218. Robinson SD, Reynolds LE, Wyder L, et al. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol 2004; 24: 2108-2114.
219. Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ibalpha supports experimental lung metastasis. Proc Natl Acad Sci USA 2007; 104: 9024-9028.
220. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 2009; 10: 1713-1717.
221. Boucharaba A, Serre GM, Guglielmi J, et al. The type I lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 2006; 103: 9643-9648.
222. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 20: 752-760.
223. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-1524.
224. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood 2009; 113: 2835-2842.
225. Kerr BA, Miocinovic R, Smith AK, et al. Comparison of tumor and microenvironment secretomes in plasma and platelets during prostrate cancer growth in a xenograft model. Neoplasia 2010; 12: 388-396.
226. Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumour growth. Blood 2008 111: 1201-1207.
227. Zaslavsky A, Baek KH, Lynch RC, et al. Platelet-derived thrombospondin-1 (TSP-1) is a critical negative regulator and potential biomarker of angiogenesis. Blood 2010; 115: 4605-4613.
228. Peterson JE, Zurakowski D, Italiano JE Jr, et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010; 8: 487-493.
229. Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation by cancer cells. J Biol Chem 2007; 282: 25993-26001.
230. Katoh N. Platelets as versatile regulators of cutaneous inflammation. J Dermatol Sci 2009; 53: 89-95.
231. O'Sullivan BP, Michelson AD. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med. 2006; 173: 483-490.
232. Garbaraviciene J, Diehl S, Varwig D, et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol 2010; 19: 736-741.
233. Wu B, Liu G, Yube K, et al. Effects of platelet release products on neutrophilic activity in human whole blood. Inflamm Res 2009; 58: 321-328.
234. Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7: 1759-1766.
235. Vlaar AP, Hofstra JJ, Kulik W, et al. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model. Blood 2010; 116: 1360-1368.
236. Antczak AJ, Singh N, Gay SR, et al. IgG-complex stimulated platelets: a source of sCD40L and RANTES in initiation of inflammatory cascade. Cell Immunol 2010; 263: 129-133.
237. Selman M, Cisneros-Lira J, Gaxiola M, et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest 2003; 123: 1633-1641.
238. Cory DB, Kiss A, Song LZ, et al. Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J 2004; 18: 995-997.
239. Asaduzzaman M, Lavasani S, Rahman M, et al. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 2009; 37: 1389-1396.
240. Menchen L, Marin-Jiminez I, Arias-Salgado EG, et al. Matrix metalloprotease 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40L. Gut 2009; 58: 920-928.
241. Schenk M, Bouchon A, Seibold F, et al. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 2007; 117: 3097-3106.
242. Tchetverikov I, Lohmander LS, Verzijl N, et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis 2005; 64: 694-698.
243. Tchetverikov I, Lard LR, De Groot J, et al. Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 1094-1099.
244. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580-583.
245. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116: 878-885.
246. Laschke MW, Dold S, Mener MD, et al. Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile-duct ligation-induced cholestasis. Br J Pharmacol 2008; 153: 148-156.
247. Zaldivar MM, Pauels K, von Hundelshausen P, et al. CXC chemokine ligand 4 (Cxcl14) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010; 51: 1345-1353.
248. Villeneuve J, Lepreux S, Mulot A, et al. A protective role for CD154 in hepatic steatosis. Hepatology 2011; 52: 1968-1979.
249. Yamakuchi M, Kirkilesz-Smith NC, Ferlito M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci USA 2007; 104: 1301-1306.
250. Morrell CN, Murata K, Swaim AM, et al. In vitro platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res 2008; 102: 777-785.
251. Sanchez M, Anitua E, Orive G, et al. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med 2009; 39: 345-354.
252. Hwang YJ, Choi JY. Addition of mesenchymal stem cells to the scaffold of platelet-rich plasma is beneficial for the reduction of the consolidation period in mandibular distraction osteogenesis. J Oral Maxillofac Surg 2010; 68: 1112-1124.
253. Maynard DM, Heijnen HF, Gahl WA, et al. The alpha granule proteome: novel proteins in normal and ghost granules in gray platelet syndrome. J Thromb Haemost 2010; 8: 1786-1796.